UniProtKB/Swiss-Prot P56539: Variant p.Gly56Ser

Caveolin-3
Gene: CAV3
Feedback?

Variant information Variant position:

56 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Serine (S) at position 56 (G56S, p.Gly56Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs72546667 [ dbSNP | Ensembl ]

Sequence information Variant position:

56 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

151 The length of the canonical sequence.
Location on the sequence:

IVKVDFEDVIAEPVGTYSFD G VWKVSYTTFTVSKYWCYRLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IVKVDFEDVIAEPVGTYSFDGVWKVSYTTFTVSKYWCYRLL

Mouse                         IVKVDFEDVIAEPEGTYSFDGVWKVSFTTFTVSKYWCYRLL

Rat                           IVKVDFEDVIAEPEGTYSFDGVWRVSYTTFTVSKYWCYRLL

Pig                           IVKVDFEDVIAEPVGTYSFDGVWKVSYTTFTVSKYWCYRLL

Bovine                        IVKVDFEDVIAEPVGTYSFDGVWKVSYTTFTVSKYWCYRLL

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 151	Caveolin-3
Topological domain	1 – 83	Cytoplasmic
Cross	38 – 38	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3)

Literature citations
Caveolin-3 in muscular dystrophy.
McNally E.M.; de Sa Moreira E.; Duggan D.J.; Bonnemann C.G.; Lisanti M.P.; Lidov H.G.W.; Vainzof M.; Passos-Bueno M.R.; Hoffman E.P.; Zatz M.; Kunkel L.M.;
Hum. Mol. Genet. 7:871-877(1998)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA]; VARIANTS SER-56 AND TRP-72; Mutations in the caveolin-3 gene: when are they pathogenic?
de Paula F.; Vainzof M.; Bernardino A.L.F.; McNally E.; Kunkel L.M.; Zatz M.;
Am. J. Med. Genet. 99:303-307(2001)
Cited for: VARIANTS SER-56; TRP-72 AND HIS-126; Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.
Vatta M.; Ackerman M.J.; Ye B.; Makielski J.C.; Ughanze E.E.; Taylor E.W.; Tester D.J.; Balijepalli R.C.; Foell J.D.; Li Z.; Kamp T.J.; Towbin J.A.;
Circulation 114:2104-2112(2006)
Cited for: VARIANTS LQT9 MET-78; THR-85; CYS-97 AND ARG-141; VARIANTS SER-56 AND TRP-72; CHARACTERIZATION OF VARIANTS LQT9 CYS-97 AND ARG-141;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.